Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and Tirzepatide — mechanism, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It has a half-life of approximately 5 days, allowing once-weekly subcutaneous dosing.
BPC-157
Tirzepatide
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
BPC-157
Tirzepatide
COA corpus from Disclosed Labs — independently tested batches only.
BPC-157
334
COAs
99.3%
Avg purity
16
Labs
Tirzepatide
306
COAs
99.7%
Avg purity
15
Labs
BPC-157 is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Tirzepatide remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage (PMID 21548867, 30915550). Preclinical tendon studies demonstrate enhanced growth hormone receptor expression in fibroblasts (PMID 25415472) and promote tendon outgrowth, cell survival, and cell migration (PMID 21030672). Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses (200–500 mcg) commonly used on the grey market, and pharmacokinetics and long-term safety in humans are not well characterized.
Key references
The SURPASS program established efficacy in type 2 diabetes, including SURPASS-2 (Frias et al., NEJM 2021), in which tirzepatide was superior to semaglutide 1 mg for A1C reduction and body weight. The SURMOUNT-1 obesity trial (Jastreboff et al., NEJM 2022) demonstrated up to approximately 20.9% mean body-weight reduction at 15 mg over 72 weeks. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed large reductions in apnea-hypopnea index in obstructive sleep apnea with obesity, supporting the 2024 FDA indication (Zepbound for moderate-to-severe OSA in adults with obesity). The SUMMIT trial (Packer et al., NEJM 2025) demonstrated a lower risk of cardiovascular death or worsening heart failure in HFpEF with obesity.
BPC-157 (Recovery) and Tirzepatide (Metabolic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs